Indeed, the treatment protocols have been optimized and targeted therapeutic agents exploiting the specificities of TNBC tumours developed, such as Poly-ADP-Ribose-Polymerase 1 inhibitors (PARPi such as Olaparib/Lynparza®, AstraZeneca) [2,7]. Here, PARP1 is linked to neoplasm.